Quality Investor

Enovis Corporation

Rank #161StartupWatchlistCompare with other stocks

ENOV · NYSE · Healthcare

Enovis Corporation (ENOV) — Rank #161 by gross profitability (GP/assets 0.36) · ROE -80.2% · Piotroski F-Score 4 / 9.

As-of 2026-10-30 · CIK 0001420800 · all metrics point-in-time as of the filing date.

About

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally.

Show more

It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation.

Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Industry
Medical Devices
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31
Website
enovis.com

Company Snapshot

P/S is the primary valuation lens for pre-profit companies.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

7,802

Industry

Medical Devices

Exchange

NYSE

9/12

Flags passed

ENOV fails 2 critical flags

Passes 9 of 12 quality flags, 1 caution

  • FAIL
    Operating margin declining

    Operating margin lower than prior year

  • FAIL
    Valuation convergence

    EPS declining, shares diluting, and revenue growth decelerating simultaneously

  • CAUTION
    Dilution above 2%

    Annual share count increase exceeds 2%. May be acceptable for high-growth companies funding talent via stock compensation

  • PASS
    Gross margin holding
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    Balance sheet stable
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.36
Return on equity
-80.2%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.55
Current ratio
1.98×
Net cash
-$1.27B

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
1.5%

Growth

1/2 pass
Revenue growth
6.7%
Piotroski F-Score
4 / 9
Share dilution
3.2%

Burn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.

Profitability

Does it make money well?

Warning: Operating margin declining · GP/assets 52nd percentile of 41 SIC 38 peers

Gross profitability (GP / assets)

0.36

Primary signal (Novy-Marx).

52nd pctl of 41 SIC 38 peers

Return on equity

-80.2%

Gross margin

59.8%

50th pctl of 41 SIC 38 peers

Revenue growth (YoY)

6.7%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

12.9%

Revenue CAGR (5Y)

14.9%

Earnings CAGR (3Y)

—

FCF CAGR (3Y)

—

Cash Flow Health

Is the cash real?

No warning flags · FCF 102% above net income

Free cash flow

$19.92M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

101.7%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

1.5%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

Caution: Dilution above 2% · net debt $1.27B, F-Score 4/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.55

8th pctl of 40 SIC 38 peers (best = lowest)

Current ratio

1.98×

23rd pctl of 40 SIC 38 peers

Quick ratio

0.74×

Net cash

-$1.27B

Cash & equivalents minus total debt.

Piotroski F-Score

4 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

Warning: Valuation convergence

Capital allocation quality

Composite score

2.3 / 5

Fair
Share count trend
3.2%1/5 Weak
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory(deleveraging)
0.5%3/5 Good

Lifecycle Phase History

20202025
Decline
Hypergrowth
Startup

Price History

ENOV-77.7% · -25.9% CAGRSPY+82.9% · +12.8% CAGR